Avoro Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 9.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,111,111 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the quarter. Alnylam […]
Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,930,079 shares of the biopharmaceutical company’s stock after buying an additional 146,236 shares during […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seventeen research firms that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 […]
Karani Asset Management LLC lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 24.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,555 shares of the biopharmaceutical company’s stock after selling 3,690 shares during the quarter. Alnylam Pharmaceuticals comprises […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They currently have a $200.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 36.05% from the […]